Babak Nemati
Babak Nemati, Ph.D., Founder, President & CEO
Babak is a 17+ year veteran of the healthcare industry, serving in executive roles at leading corporations, such as Johnson & Johnson. While at J&J, he served as the Director of Surgical Oncology for Ethicon and Ethicon Endo-surgery, and Chair of Medical Optics for the Corporate Office of Science and Technology. In these roles, he was responsible for strategic planning for new franchises within the Corporation, assessment of new and emerging technologies (sourced globally) for their strategic fit, technical merit, and commercial viability, and leading or contributing to licensing and acquisition negotiations with emerging companies.
Outside of J&J, Babak has served in executive roles for emerging medical device and biotechnology companies, in a wide range of specialties ranging from oncology, general surgery, ophthalmology, and women's health, to dermatology and plastic surgery. He has a proven track record of success in a diverse range of operating responsibilities such as research and development, global program management, new business development, marketing and sales, corporate planning, and strategic management of clinical and regulatory functions. Throughout his career, Babak has demonstrated a unique ability in developing and implementing focused strategic plans that maximize a company's competencies through identification and development of business opportunities both internal and external to an organization.
He holds several patents in the field of medical optics, and has published a number of original articles in refereed journals. Additionally he has served as a member of the Advisory Board for the Medical Technology Program of Lawrence Livermore National Laboratory, Plebys International, and Nanoverse. His academic training includes a Bachelor of Arts in Physics (with Special Honors), Bachelor of Science in Mathematics, and a Master's and a doctoral degree in Electrical and Biomedical Engineering, all from the University of Texas at Austin.
Babak is a 17+ year veteran of the healthcare industry, serving in executive roles at leading corporations, such as Johnson & Johnson. While at J&J, he served as the Director of Surgical Oncology for Ethicon and Ethicon Endo-surgery, and Chair of Medical Optics for the Corporate Office of Science and Technology. In these roles, he was responsible for strategic planning for new franchises within the Corporation, assessment of new and emerging technologies (sourced globally) for their strategic fit, technical merit, and commercial viability, and leading or contributing to licensing and acquisition negotiations with emerging companies.
Outside of J&J, Babak has served in executive roles for emerging medical device and biotechnology companies, in a wide range of specialties ranging from oncology, general surgery, ophthalmology, and women's health, to dermatology and plastic surgery. He has a proven track record of success in a diverse range of operating responsibilities such as research and development, global program management, new business development, marketing and sales, corporate planning, and strategic management of clinical and regulatory functions. Throughout his career, Babak has demonstrated a unique ability in developing and implementing focused strategic plans that maximize a company's competencies through identification and development of business opportunities both internal and external to an organization.
He holds several patents in the field of medical optics, and has published a number of original articles in refereed journals. Additionally he has served as a member of the Advisory Board for the Medical Technology Program of Lawrence Livermore National Laboratory, Plebys International, and Nanoverse. His academic training includes a Bachelor of Arts in Physics (with Special Honors), Bachelor of Science in Mathematics, and a Master's and a doctoral degree in Electrical and Biomedical Engineering, all from the University of Texas at Austin.
Debra Robertson
Joseph Sinkule
Rolfe Anderson
Debra Robertson, Ph.D., Consulting Affiliate, Technology Assessment, Strategic IP Development
Debbie is an experienced business analyst serving SI's strategic consulting practices by focusing on key issues that small start up companies face in their growth cycle, ranging from product development issues, to proper positioning of emerging technologies in the market place, to development of a strong defensive and offensive intellectual property portfolio. Debbie has significant expertise in technical, clinical and market risk analysis of medical device opportunities, specialty pharmaceuticals, life science products and new chemical entities, and she serves as a specialist in global market evaluation including competitive assessment of technologies and products for startup, high growth and established corporate environments. Debbie has served as Executive Director of Intellectual Property at Epicyte Pharmaceuticals, Inc., Director of Intellectual Property at Sequenom, a scientific advisor for Lyon & Lyon, LLP, and as a freelance biotechnology writer for Nature Biotechnology. With over 15 years of experience in strategic corporate and business development in the biotechnology industry, Debbie was recognized as an "outstanding woman in business" by San Diego Business Journal.
Debbie holds a doctoral degree in microbiology from University of California at Los Angeles, a BA in Biology from University of California at San Diego, and she completed her postdoctoral training in the Departments of Molecular Biology and Chemistry at The Scripps Research Institute.
Debbie is an experienced business analyst serving SI's strategic consulting practices by focusing on key issues that small start up companies face in their growth cycle, ranging from product development issues, to proper positioning of emerging technologies in the market place, to development of a strong defensive and offensive intellectual property portfolio. Debbie has significant expertise in technical, clinical and market risk analysis of medical device opportunities, specialty pharmaceuticals, life science products and new chemical entities, and she serves as a specialist in global market evaluation including competitive assessment of technologies and products for startup, high growth and established corporate environments. Debbie has served as Executive Director of Intellectual Property at Epicyte Pharmaceuticals, Inc., Director of Intellectual Property at Sequenom, a scientific advisor for Lyon & Lyon, LLP, and as a freelance biotechnology writer for Nature Biotechnology. With over 15 years of experience in strategic corporate and business development in the biotechnology industry, Debbie was recognized as an "outstanding woman in business" by San Diego Business Journal.
Debbie holds a doctoral degree in microbiology from University of California at Los Angeles, a BA in Biology from University of California at San Diego, and she completed her postdoctoral training in the Departments of Molecular Biology and Chemistry at The Scripps Research Institute.
Joseph Sinkule, Ph.D., Consulting Affiliate, Clinical and Regulatory Development
Joe is a seasoned pharmaceutical executive with over 24 years of pharmaceutical and biotechnology management experience in the research, development, manufacturing, project management and commercialization of drugs, devices, and biologics. Joe is a prolific entrepreneur, with in-depth experience in having founded several early stage biotechnology companies in the past decade. He has been directly involved in the development and commercialization of five vaccine products submitted to FDA.
Previously, Joe was the Director of EER Medical Systems, Inc., a US-based clinical research organization (CRO) where his responsibilities, including advising the company's clients in all aspects of clinical and regulatory affairs and GMP manufacturing. Joe also founded and served as President/COO and Director of Iatros BioPharma Inc., a genetics vaccine company where, as President, he negotiated and licensed the company's technologies, obtained private funding, and advanced the technologies through Phase II clinical trials. Previously, he held senior management positions with Immunex Corporation as Director of Clinical Research and was a key team member on the product development team for the commercialization of recombinant GM-CSF and the clinical introduction of recombinant IL-3 and recombinant IL-1.
Earlier in his career, Joe was Senior Vice President of Research and Development at a NASDAQ-listed biotech company and contract GMP manufacturing organization called Techniclone International. Joe was instrumental in converting a public company that was making research-grade biological products (recombinant proteins and monoclonal antibodies) into a fully compliant GMP production facility for clinical-grade biologics. Joe provided pharmaceutical consulting services for nearly five years before joining EER in 1996. He has many years of executive management experience and is capable of managing several difficult projects simultaneously and taking them from planning and initiation to completion. Within Strategic Intelligence, Joe is actively involved in clinical and regulatory development consulting engagements.
Joe is a seasoned pharmaceutical executive with over 24 years of pharmaceutical and biotechnology management experience in the research, development, manufacturing, project management and commercialization of drugs, devices, and biologics. Joe is a prolific entrepreneur, with in-depth experience in having founded several early stage biotechnology companies in the past decade. He has been directly involved in the development and commercialization of five vaccine products submitted to FDA.
Previously, Joe was the Director of EER Medical Systems, Inc., a US-based clinical research organization (CRO) where his responsibilities, including advising the company's clients in all aspects of clinical and regulatory affairs and GMP manufacturing. Joe also founded and served as President/COO and Director of Iatros BioPharma Inc., a genetics vaccine company where, as President, he negotiated and licensed the company's technologies, obtained private funding, and advanced the technologies through Phase II clinical trials. Previously, he held senior management positions with Immunex Corporation as Director of Clinical Research and was a key team member on the product development team for the commercialization of recombinant GM-CSF and the clinical introduction of recombinant IL-3 and recombinant IL-1.
Earlier in his career, Joe was Senior Vice President of Research and Development at a NASDAQ-listed biotech company and contract GMP manufacturing organization called Techniclone International. Joe was instrumental in converting a public company that was making research-grade biological products (recombinant proteins and monoclonal antibodies) into a fully compliant GMP production facility for clinical-grade biologics. Joe provided pharmaceutical consulting services for nearly five years before joining EER in 1996. He has many years of executive management experience and is capable of managing several difficult projects simultaneously and taking them from planning and initiation to completion. Within Strategic Intelligence, Joe is actively involved in clinical and regulatory development consulting engagements.
Rolfe Anderson, Ph.D., Consulting Affiliate, Technology Assessment Services
Rolfe Anderson has over 15 years of experience in engineering R&D, product definition and project management across the drug delivery, life sciences instrumentation, and microfabrication businesses. He served as Director of New Technology Development at ALZA Corporation from 2003 to 2006 where he managed the research and development of innovative drug-delivery methods and devices. He created an interdisciplinary “innovation generator” team that identified and evaluated over 40 unique drug delivery concepts with 12 proof-of-concept demonstrations resulting in filing more than 20 invention records, over 11 patent filings, and launching over 6 new projects in a two year period. Cross-company expertise was leveraged by assembling a Science and Technology Review Board composed of MD’s, scientists, and technologists across 9 J&J companies that met regularly to review the drug-delivery proposals.
Prior to that from 2000 to 2003 Rolfe was Senior Director of Device Integration at ACLARA BioSciences where he defined a new product (Plurex) that provides intensive multiplexing for genotyping assays, for which he built and led a team of 30+ from concept through launch.
From 1995 to 2000 Rolfe worked at Affymetrix as Group Leader and Manager of Integrated Device Development where he successfully developed devices that carry out multi-step assays to analyze tissue samples using GeneChip arrays. These devices combine processes such as fluidic manipulation, nucleic-acid extraction, enzymatic reactions (such as PCR), and hybridization into a miniaturized format smaller than a credit card. For example, a system, aimed at HIV polymorphism detection executes 11 sequential processes encompassing a complete procedure from sample extraction through hybridization in a single miniature device and was featured in Science Magazine.
Rolfe’s broad technical expertise and training span the fields of chemical engineering, electrochemistry, electrical engineering, device physics, MEMS, molecular biology, thin film magnetic head development and manufacture, integrated valve development, microfabrication, integrated sensors and actuators, and human anatomy and physiology. Rolfe holds a B.S. in chemical engineering from University of Washington, an M.S. in electrical engineering and a Ph.D. degree in chemical engineering from the University of California , Berkeley.
Rolfe is also the founder and coordinator of the Bay Area MEMS Journal Club, a monthly forum on microfabricated-device development, fabrication, and applications. Founded in 1993, the club has grown to over 1000 members with monthly attendance of at least 40 scientists representing well over 20 companies, 3 universities and 4 national labs. He serves on the editorial board of Biomedical Microdevices, holds several issued patents in microfluidics and microactuation, numerous publications and has delivered many invited presentations both in the U.S. and Europe.
Rolfe Anderson has over 15 years of experience in engineering R&D, product definition and project management across the drug delivery, life sciences instrumentation, and microfabrication businesses. He served as Director of New Technology Development at ALZA Corporation from 2003 to 2006 where he managed the research and development of innovative drug-delivery methods and devices. He created an interdisciplinary “innovation generator” team that identified and evaluated over 40 unique drug delivery concepts with 12 proof-of-concept demonstrations resulting in filing more than 20 invention records, over 11 patent filings, and launching over 6 new projects in a two year period. Cross-company expertise was leveraged by assembling a Science and Technology Review Board composed of MD’s, scientists, and technologists across 9 J&J companies that met regularly to review the drug-delivery proposals.
Prior to that from 2000 to 2003 Rolfe was Senior Director of Device Integration at ACLARA BioSciences where he defined a new product (Plurex) that provides intensive multiplexing for genotyping assays, for which he built and led a team of 30+ from concept through launch.
From 1995 to 2000 Rolfe worked at Affymetrix as Group Leader and Manager of Integrated Device Development where he successfully developed devices that carry out multi-step assays to analyze tissue samples using GeneChip arrays. These devices combine processes such as fluidic manipulation, nucleic-acid extraction, enzymatic reactions (such as PCR), and hybridization into a miniaturized format smaller than a credit card. For example, a system, aimed at HIV polymorphism detection executes 11 sequential processes encompassing a complete procedure from sample extraction through hybridization in a single miniature device and was featured in Science Magazine.
Rolfe’s broad technical expertise and training span the fields of chemical engineering, electrochemistry, electrical engineering, device physics, MEMS, molecular biology, thin film magnetic head development and manufacture, integrated valve development, microfabrication, integrated sensors and actuators, and human anatomy and physiology. Rolfe holds a B.S. in chemical engineering from University of Washington, an M.S. in electrical engineering and a Ph.D. degree in chemical engineering from the University of California , Berkeley.
Rolfe is also the founder and coordinator of the Bay Area MEMS Journal Club, a monthly forum on microfabricated-device development, fabrication, and applications. Founded in 1993, the club has grown to over 1000 members with monthly attendance of at least 40 scientists representing well over 20 companies, 3 universities and 4 national labs. He serves on the editorial board of Biomedical Microdevices, holds several issued patents in microfluidics and microactuation, numerous publications and has delivered many invited presentations both in the U.S. and Europe.
Tom Marsh
R. Michael Scarano Jr.
David L. Rosen
Tom Marsh, Consulting Affiliate, Corporate Finance & Venture Development
Tom Marsh has served in the capacity of CEO, CFO, COO and Director in several San Diego companies after moving here in 1984. His experience includes startup, turnaround and growth situations in the information, medical device, investment banking, and software industries, both public and private companies. He brings particular expertise in the disciplines of marketing, sales and financial management. In an entrepreneurial environment, he can switch effortlessly from marketing strategy to closing a sale, from investor pitch to accounting details, from inspiring the team to an exit decision and interview. He works best as part of the management group to a brilliant technical team.
Tom is currently Managing Partner of Flywheel Fx, a provider of outsourced marketing services, sales operation and business development for small private and public companies. Prior to founding Flywheel Fx, Tom was Chairman and CEO of NeuroPower, Inc. and PriMetricaAsia, a marketing database solutions and services company based in Singapore. From 2004 to 2006, Marsh served as CEO of Viking Systems, Inc. (VKSY.OB). Viking was founded in 2003 with the acquisition of a public shell and the subsequent acquisition of a 3-D surgical vision system business. Marsh lead the company through several funding rounds raising over $14 million and building the sales, marketing and clinical organization.
Prior to founding Viking, Marsh was partner and co-founder of Marsh+Flagg, a merger and acquisition advisory firm with offices in La Jolla, Newport Beach, and Stuttgart, Germany. During this time he helped restart a public procurement software company through completion of two acquisitions. During this time he served as CFO and Director. While at Marsh+Flagg, he worked with numerous clients on acquisitions and financing engagements.
After majoring in economics at Williams College in Massachusetts, Marsh began his career with a start up, Marsh Products, Inc., in 1976 providing engineering services and products to McDonalds Corporation. He served as President of the company until 1983. In 1984, he acquired a division of General Atomics in San Diego that provided computer systems and automation to the oil industry for retail stations and distribution terminals. He has lived in San Diego since 1984, serving first as CEO of Emark Corporation and then from 1995 until 2000 as COO of Co-Mack Technology.
Tom Marsh has served in the capacity of CEO, CFO, COO and Director in several San Diego companies after moving here in 1984. His experience includes startup, turnaround and growth situations in the information, medical device, investment banking, and software industries, both public and private companies. He brings particular expertise in the disciplines of marketing, sales and financial management. In an entrepreneurial environment, he can switch effortlessly from marketing strategy to closing a sale, from investor pitch to accounting details, from inspiring the team to an exit decision and interview. He works best as part of the management group to a brilliant technical team.
Tom is currently Managing Partner of Flywheel Fx, a provider of outsourced marketing services, sales operation and business development for small private and public companies. Prior to founding Flywheel Fx, Tom was Chairman and CEO of NeuroPower, Inc. and PriMetricaAsia, a marketing database solutions and services company based in Singapore. From 2004 to 2006, Marsh served as CEO of Viking Systems, Inc. (VKSY.OB). Viking was founded in 2003 with the acquisition of a public shell and the subsequent acquisition of a 3-D surgical vision system business. Marsh lead the company through several funding rounds raising over $14 million and building the sales, marketing and clinical organization.
Prior to founding Viking, Marsh was partner and co-founder of Marsh+Flagg, a merger and acquisition advisory firm with offices in La Jolla, Newport Beach, and Stuttgart, Germany. During this time he helped restart a public procurement software company through completion of two acquisitions. During this time he served as CFO and Director. While at Marsh+Flagg, he worked with numerous clients on acquisitions and financing engagements.
After majoring in economics at Williams College in Massachusetts, Marsh began his career with a start up, Marsh Products, Inc., in 1976 providing engineering services and products to McDonalds Corporation. He served as President of the company until 1983. In 1984, he acquired a division of General Atomics in San Diego that provided computer systems and automation to the oil industry for retail stations and distribution terminals. He has lived in San Diego since 1984, serving first as CEO of Emark Corporation and then from 1995 until 2000 as COO of Co-Mack Technology.
R. Michael Scarano, Jr., Esq., Consulting Affiliate, Reimbursement Strategy
R. Michael Scarano, Jr. is lead outside counsel to SI on reimbursement strategy matters. He also serves as a partner and co-chair of Foley & Lardner's Life Sciences Industry Team and is a member of the firm's Health Care Industry Team.
In his legal practice with Foley & Lardner, Mike has represented a wide variety of health care clients, including medical device companies, private and governmental hospitals and their medical staffs, nursing homes, medical groups, independent practice associations (IPAs), management services organizations (MSOs), emergency medical services (EMS) providers, public EMS agencies, diagnostic test providers and professional associations. His primary areas of practice include reimbursement, fraud and abuse/compliance, managed care, allied health professions, EMS law, and general business transactions such as entity formation and sales/acquisitions.
Mike was selected for inclusion in the 2007 edition of The Best Lawyers in America®. He was also named a 2007 Southern California "Super Lawyer" in San Diego by Law & Politics Media, Inc. He is the co-chair of the Health Law Committee of the State Bar of California for 2006-2007.
Mike speaks regularly before health care professional organizations and has published numerous articles on a variety of health law topics. He is a member of the Healthcare Financial Management Association (HFMA) and former member of the board of directors of the San Diego/Imperial County Chapter of HFMA. Mike has also been an adjunct professor of health law in the Master of Business Administration programs at National University and Webster University and a guest lecturer in the Graduate Masters of Public Health Program at San Diego State University. He is a regular columnist for EMS Insider.
Mike is a 1984 graduate of Boalt Hall School of Law at the University of California at Berkeley, where he was an associate editor of the Ecology Law Quarterly. He received his Bachelor of Arts degree, with academic distinction, from the University of California at Berkeley in 1978.
R. Michael Scarano, Jr. is lead outside counsel to SI on reimbursement strategy matters. He also serves as a partner and co-chair of Foley & Lardner's Life Sciences Industry Team and is a member of the firm's Health Care Industry Team.
In his legal practice with Foley & Lardner, Mike has represented a wide variety of health care clients, including medical device companies, private and governmental hospitals and their medical staffs, nursing homes, medical groups, independent practice associations (IPAs), management services organizations (MSOs), emergency medical services (EMS) providers, public EMS agencies, diagnostic test providers and professional associations. His primary areas of practice include reimbursement, fraud and abuse/compliance, managed care, allied health professions, EMS law, and general business transactions such as entity formation and sales/acquisitions.
Mike was selected for inclusion in the 2007 edition of The Best Lawyers in America®. He was also named a 2007 Southern California "Super Lawyer" in San Diego by Law & Politics Media, Inc. He is the co-chair of the Health Law Committee of the State Bar of California for 2006-2007.
Mike speaks regularly before health care professional organizations and has published numerous articles on a variety of health law topics. He is a member of the Healthcare Financial Management Association (HFMA) and former member of the board of directors of the San Diego/Imperial County Chapter of HFMA. Mike has also been an adjunct professor of health law in the Master of Business Administration programs at National University and Webster University and a guest lecturer in the Graduate Masters of Public Health Program at San Diego State University. He is a regular columnist for EMS Insider.
Mike is a 1984 graduate of Boalt Hall School of Law at the University of California at Berkeley, where he was an associate editor of the Ecology Law Quarterly. He received his Bachelor of Arts degree, with academic distinction, from the University of California at Berkeley in 1978.
David L. Rosen, B.S. Pharm, J.D., Consulting Affiliate, Regulatory Strategy
David Rosen is lead outside counsel to Strategic Intelligence on regulatory strategy matters, and he is also a partner and co-chair of Foley & Lardner's Life Sciences Industry Team. He is also a member of the firm's Public Affairs Practice and the Health Care, Nanotechnology and Food Industry Teams.
David has extensive experience in health law, life sciences, and food and drug regulation, including a range of Food and Drug Administration (FDA) regulatory issues affecting prescription and over-the-counter pharmaceuticals, medical devices and biologics. David was formerly a partner with several international the law firms. He was also employed by the FDA for 14 years, progressing to various supervisory positions involving virtually all aspects related to the drug approval process and related compliance activity.
David is a frequent speaker on medical device and drug issues. He has spoken before national and international audiences on how to expedite product clearance and approval; combination products; clinical trial issues; follow on biologics; the ANDA submission and review process and on the IND and expedited drug development, review, and approval processes. He has made presentations before investment analysts and managers of venture capital on the impact of FDA on the medical device, drug and biotech industry. David earned his J.D. at The Catholic University of America, Columbus School of Law (1991). He also holds a Bachelor of Science degree from the University of Connecticut School of Pharmacy (1978). David is admitted to practice in the District of Columbia and Maryland.
David Rosen is lead outside counsel to Strategic Intelligence on regulatory strategy matters, and he is also a partner and co-chair of Foley & Lardner's Life Sciences Industry Team. He is also a member of the firm's Public Affairs Practice and the Health Care, Nanotechnology and Food Industry Teams.
David has extensive experience in health law, life sciences, and food and drug regulation, including a range of Food and Drug Administration (FDA) regulatory issues affecting prescription and over-the-counter pharmaceuticals, medical devices and biologics. David was formerly a partner with several international the law firms. He was also employed by the FDA for 14 years, progressing to various supervisory positions involving virtually all aspects related to the drug approval process and related compliance activity.
David is a frequent speaker on medical device and drug issues. He has spoken before national and international audiences on how to expedite product clearance and approval; combination products; clinical trial issues; follow on biologics; the ANDA submission and review process and on the IND and expedited drug development, review, and approval processes. He has made presentations before investment analysts and managers of venture capital on the impact of FDA on the medical device, drug and biotech industry. David earned his J.D. at The Catholic University of America, Columbus School of Law (1991). He also holds a Bachelor of Science degree from the University of Connecticut School of Pharmacy (1978). David is admitted to practice in the District of Columbia and Maryland.
David Stroup
Kory Razaghi
David Stroup, Consulting Affiliate, Design and Manufacturing Automation
Mr. Stroup has vast experience in automated manufacturing and processing systems for the medical device, bio-diagnostic and pharmaceutical fields. David is an expert in the conceptualization and design of complex automated process and manufacturing systems and has extensive knowledge and know how in product and process development with an emphasis on automated manufacturability. In recent years David has focused on product development and generated a portfolio of proprietary designs in the field of disposable medical and bio-diagnostic devices. Previously, David founded and served as the Chief Executive Officer for Prodosyst Automation. David grew and diversified customer list to include several Fortune 500 companies. An exemplary list of client companies include Johnson & Johnson, Abbott Laboratories, Guidant Corporation, Cardinal Health, Tyco Electronics, Welch Allyn, and C R Bard. David applies his expertise at the foundation level of development producing designs with a strong emphasis on manufacturability. David leads engineering project management, design, and manufacturing engagements for our clients.
David holds a BS in Mechanical Engineering from San Diego State University, and has invented, developed, and engineered multiple disposable medical and bio-diagnostic devices.
Mr. Stroup has vast experience in automated manufacturing and processing systems for the medical device, bio-diagnostic and pharmaceutical fields. David is an expert in the conceptualization and design of complex automated process and manufacturing systems and has extensive knowledge and know how in product and process development with an emphasis on automated manufacturability. In recent years David has focused on product development and generated a portfolio of proprietary designs in the field of disposable medical and bio-diagnostic devices. Previously, David founded and served as the Chief Executive Officer for Prodosyst Automation. David grew and diversified customer list to include several Fortune 500 companies. An exemplary list of client companies include Johnson & Johnson, Abbott Laboratories, Guidant Corporation, Cardinal Health, Tyco Electronics, Welch Allyn, and C R Bard. David applies his expertise at the foundation level of development producing designs with a strong emphasis on manufacturability. David leads engineering project management, design, and manufacturing engagements for our clients.
David holds a BS in Mechanical Engineering from San Diego State University, and has invented, developed, and engineered multiple disposable medical and bio-diagnostic devices.
Kory Razaghi MS, MBA, Advisor, Corporate and Financial Strategy
Kory has over 10 years of investment banking, business development, sales and marketing, and R&D experience in various segments of the life science industry. Previously, Kory was leading business development, strategic consulting, and competitive intelligence gathering and analysis for xIQ Ventures. Prior to xIQ Ventures, Kory served as an Associate at Waveland Capital Group's private equity team. He was responsible for initial screening, due diligence, market assessment, valuation analysis, and advising on transaction structure, including securing licensing agreements for prospective clients and portfolio companies. Kory also played an integral role in the capital formation and fund raising activities on behalf of client companies. Kory has worked as a biochemist for public and private biotechnology companies. He has worked on a variety of projects including research and development of pre-clinical anti-hemorrhagic drugs, genetically enhanced agricultural products, and analytical chemistry products and services.
Kory holds an MBA in Finance and Marketing from the University of California at Irvine, an MS in Biomedical Sciences from University of New Mexico, and a BS in Chemistry from the University of Utah.
Kory has over 10 years of investment banking, business development, sales and marketing, and R&D experience in various segments of the life science industry. Previously, Kory was leading business development, strategic consulting, and competitive intelligence gathering and analysis for xIQ Ventures. Prior to xIQ Ventures, Kory served as an Associate at Waveland Capital Group's private equity team. He was responsible for initial screening, due diligence, market assessment, valuation analysis, and advising on transaction structure, including securing licensing agreements for prospective clients and portfolio companies. Kory also played an integral role in the capital formation and fund raising activities on behalf of client companies. Kory has worked as a biochemist for public and private biotechnology companies. He has worked on a variety of projects including research and development of pre-clinical anti-hemorrhagic drugs, genetically enhanced agricultural products, and analytical chemistry products and services.
Kory holds an MBA in Finance and Marketing from the University of California at Irvine, an MS in Biomedical Sciences from University of New Mexico, and a BS in Chemistry from the University of Utah.